Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia

Diagnostic Pathology

Xueqian Yan¹  Fang Xiao¹  Wen Fan¹  Yangping Zhang¹  Ren’an Chen¹  Li Liu¹ 

[1] Department of Haematology, Tangdu Hospital, Fourth Military Medical University, No.1, Xinsi Road, Xi’an 710038, Shaanxi, People’s Republic of China

关键词: Prognosis;    Acute myeloid leukemia;    miR-328;    Circulating;   

Others  :  1220746
DOI  :  10.1186/s13000-015-0345-6

 received in 2015-01-11, accepted in 2015-07-09,  发布年份 2015

【 摘 要 】

Background

Dysregulation of circulating miR-328 has been identified in several tumors and is associated with prognosis of patients. However, the expression pattern of miR-328 and the impact on prognosis has not yet been studied in acute myeloid leukemia (AML). The purpose of this study is to investigate the expression status of miR-328 and its clinical significance in AML patients.

Methods

RNA was extracted from plasma of 176 patients with newly diagnosed AML and 70 healthy volunteers. The miR-328 expression was examined by Realtime quantitative PCR. The association of circulating miR-328 expression with clinicopathological factors and prognosis of AML patients was statistically analyzed.

Results

The expression of miR-328 was significantly downregulated in AML patients (median value 22.99, range: 3.63-242.0) compared with those of healthy controls (median value 89.17, range: 12.05-397.7; P < 0.001), and miR-328 expression was markedly increased in patients after treatment than before (23.40 ± 1.76 vs. 46.61 ± 3.83, P < 0.001). Moreover, low levels of miR-328 were associated with a higher white blood cell count and BM blast count (P = 0.026 and P = 0.003, respectively), and lower hemoglobin and platelet count (P = 0.004 and P = 0.022, respectively). Patients with low miR-328 expression had a relatively poor overall survival (P = 0.022) and shorter relapse-free survival (P = 0.008) than those with high miR-328 expression. In addition, low miR-328 expression was an independent prognostic factors for both OS (P = 0.017) and RFS (P = 0.023).

Conclusions

Circulating miR-328 downregulation is a common event and is associated with poor clinical outcome in AML patients.

【 授权许可】

   
2015 Liu et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013; 381(9865):484-95.
• [2]Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014; 15(9):e382-94.
• [3]Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009; 2:23. BioMed Central Full Text
• [4]Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54.
• [5]Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97.
• [6]Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al.. MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8.
• [7]Takada S, Yamashita Y, Berezikov E, Hatanaka H, Fujiwara SI, Kurashina K et al.. MicroRNA expression profiles of human leukemias. Leukemia. 2008; 22(6):1274-8.
• [8]Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol (Dordr). 2012; 35(5):317-34.
• [9]Sun SM, Rockova V, Bullinger L, Dijkstra MK, Dohner H, Lowenberg B et al.. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia. 2013; 27(1):100-6.
• [10]Chen XX, Lin J, Qian J, Qian W, Yang J, Ma JC et al.. Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. Clin Biochem. 2014; 47(1–2):63-6.
• [11]Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S et al.. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012; 119(10):2314-24.
• [12]Li Y, Lin J, Yang J, Qian J, Qian W, Yao DM et al.. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leuk Res. 2013; 37(12):1642-7.
• [13]Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev. 2011; 12(5):1117-25.
• [14]Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One. 2011; 6(6): Article ID e20769
• [15]Cheng G. Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015; 81C:75-93.
• [16]Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R et al.. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010; 140(5):652-65.
• [17]Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W et al.. MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS One. 2012; 7(10): Article ID e47270
• [18]Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D et al.. Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. Int J Mol Sci. 2013; 14(5):10332-42.
• [19]He F, Lv P, Zhao X, Wang X, Ma X, Meng W et al.. Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol Cell Biochem. 2014; 394(1–2):137-44.
• [20]Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. France: IARC Press. 2008;2008.
• [21]Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al.. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(4):620-5.
• [22]Lo Coco F, Foa R. Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia. Eur J Haematol. 1995; 55(1):1-9.
• [23]Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al.. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96(13):4075-83.
• [24]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001; 25(4):402-8.
• [25]Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8.
• [26]Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014; 24(16):R762-76.
• [27]Yu J, Wang Y, Dong R, Huang X, Ding S, Qiu H. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol. 2012; 138(4):671-4.
• [28]Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL, Yao GL. Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol. 2014; 20(22):6906-11.
• [29]Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, Badran R et al.. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 2013; 11:31. BioMed Central Full Text
• [30]Yuan J, Zheng Z, Zheng Y, Lu X, Xu L, Lin L. microRNA-328 is a favorable prognostic marker in human glioma via suppressing invasive and proliferative phenotypes of malignant cells. Int J Neurosci. 2015:1–22. doi:10.3109/00207454.2014.1002610.
• [31]Chen CH, Cheng CY, Chen YC, Sue YM, Liu CT, Cheng TH et al.. MicroRNA-328 inhibits renal tubular cell epithelial-to-mesenchymal transition by targeting the CD44 in pressure-induced renal fibrosis. PLoS One. 2014; 9(6): Article ID e99802